Rhythm Pharmaceuticals focuses on rare genetic disorders of obesity and its lead drug, Imcivree, treats obesity due to specific genetic deficiencies. Imcivree's use is limited to specific genetic ...
The last time I spoke about Rhythm Pharmaceuticals, Inc. (RYTM) it was in a Seeking Alpha article entitled "Rhythm: Late-Stage Study Win Brings About Change For Rare Obesity Disorder." With respect to ...
Rhythm Pharmaceuticals' lone approved product currently generates minimal sales. However, recent clinical progress could help change that in the coming years. The biotech is a little risky, but it ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results